Mylan

OGIVRI - Cost

Updated as of: July 1st, 2024

HCPCS:

Q5114

HCPCS Code Descriptor:

Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg

Medicare Payment Limit:

The Ogivri Medicare Payment Limit is $55.784.

Average Sale Price:

OGIVRI ASP cost available once logged in. Ogivri is a biosimilar drug making the ASP calculation more complex. Ogivri's ASP is based on the average sale price of its biosimilar reference drug.

Medicare Co-Insurance Percentage:

The Ogivri Medicare Co-Insurance percentage is 20%. Ogivri's Medicare Co-Insurance amount is $11.157

APC Code:

The Ogivri APC Code is: 9341

APC Payment Limit:

The APC Payment Limit for OGIVRI is available. Login to view.

Ogivri Cost Information:

Ogivri (Q5114) is a trastuzumab biosimilar to the reference product Herceptin (J9355). Q5114 became effective in July of 2019 and maintained a consistent WAC and AWP until October of 2023. Ogivri’s ASP was first listed in January of 2020 and quickly began to decrease facing intense competition from other trastuzumab biosimilars. In October of 2023, Ogivri dropped their list pricing by more than 25%.

ACCESS PRICING AND MORE BY REGISTERING

Ogivri’s wholesale acquisition cost (WAC) information was last updated on:
September 21, 2023
Ogivri’s average wholesale price (AWP) information was last updated on:
September 21, 2023